Page last updated: 2024-12-11

1-(1,3-benzodioxol-5-yl)-3-(6-methyl-2-pyridinyl)urea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(1,3-benzodioxol-5-yl)-3-(6-methyl-2-pyridinyl)urea is a chemical compound with a complex structure. It's likely a synthetic molecule, and the specific significance of its structure would depend on the context of its research.

**Here's what we can gather from its name and structure:**

* **1-(1,3-benzodioxol-5-yl):** This part indicates a **benzodioxole ring** substituted at the 5-position. Benzodioxoles are common structural motifs found in many natural products and pharmaceuticals, often associated with biological activity.
* **3-(6-methyl-2-pyridinyl):** This part indicates a **pyridinyl ring** substituted at the 2-position and with a methyl group at the 6-position. Pyridine rings are also frequently found in pharmaceuticals and natural products, often contributing to their biological activity.
* **Urea:** This is a functional group known for its ability to form hydrogen bonds. Many urea derivatives have pharmacological properties, including acting as enzyme inhibitors or targeting specific receptors.

**Potential Research Importance:**

Given its structure, 1-(1,3-benzodioxol-5-yl)-3-(6-methyl-2-pyridinyl)urea could be of interest for research in several areas:

* **Pharmacology:** This compound might show activity as a drug candidate due to its combination of benzodioxole and pyridinyl rings, which are associated with biological effects. It could be investigated for various therapeutic applications, such as anti-cancer, anti-inflammatory, or anti-microbial effects.
* **Materials Science:** The presence of the urea group suggests this compound could have properties related to polymers or coatings due to its potential for hydrogen bonding.
* **Organic Chemistry:** This compound could be a valuable synthetic building block or intermediate for the development of new molecules with desired properties.

**To understand the specific research importance of this compound, you would need more information:**

* **The research context:** What is the specific research question being investigated?
* **The experimental data:** What are the observed effects of this compound?
* **The specific applications:** What is the potential use of this compound in a particular field?

Without this additional information, it's difficult to pinpoint the exact reason why this compound is being studied.

Cross-References

ID SourceID
PubMed CID6465706
CHEMBL ID1464737
CHEBI ID116308

Synonyms (13)

Synonym
HMS2596C12
MLS000679398
n-1,3-benzodioxol-5-yl-n'-(6-methyl-2-pyridinyl)urea
smr000297565
1-(1,3-benzodioxol-5-yl)-3-(6-methylpyridin-2-yl)urea
STK469982
AKOS003339490
CHEMBL1464737
HMS3381P07
Q27199166
1-(1,3-benzodioxol-5-yl)-3-(6-methyl-2-pyridinyl)urea
CHEBI:116308
n-(1,3-benzodioxol-5-yl)-n'-(6-methyl-2-pyridyl)urea
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzodioxoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency2.68550.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency0.50120.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency7.49930.004110.890331.5287AID504466; AID504467
Microtubule-associated protein tauHomo sapiens (human)Potency12.58930.180013.557439.8107AID1460
glucocerebrosidaseHomo sapiens (human)Potency12.58930.01268.156944.6684AID2101
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency1.77830.01262.451825.0177AID485313
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency11.58210.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency14.12543.548119.542744.6684AID743266
importin subunit beta-1 isoform 1Homo sapiens (human)Potency29.09295.804836.130665.1308AID540253
ras-related protein Rab-9AHomo sapiens (human)Potency2.23870.00022.621531.4954AID485297
snurportin-1Homo sapiens (human)Potency29.09295.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency29.09295.804816.996225.9290AID540253
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency7.07950.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency7.07950.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency7.07950.15855.287912.5893AID540303
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]